Results 261 to 270 of about 160,832 (337)

Therapeutic Potential of Melatonin in Gastrointestinal Cancers: Molecular Mechanisms, Preclinical Evidence and Clinical Implications

Journal of Pineal Research, Volume 78, Issue 1, January 2026.
ABSTRACT Gastrointestinal (GI) cancers remain a leading cause of global morbidity and mortality, necessitating novel therapeutic strategies. Melatonin (MEL), an indoleamine with pleiotropic biological activities, has emerged as a promising adjuvant in oncology due to its antiproliferative, proapoptotic, and antioxidant properties.
Maciej Gonciarz, Benita Wiatrak, Iga Lombard, Łukasz Konecki, Joanna Sarbinowska   +4 more
wiley   +1 more source

Analysis of the efficacy and prognostic factors of gemcitabine combined with oxaliplatin in non-Hodgkin lymphoma. [PDF]

Oncol Lett
Zhang X, Li G, Liu F, Shi R, Wen J, Wu W, Dai J.   +6 more
europepmc   +1 more source

First-line tislelizumab and ociperlimab combined with gemcitabine and cisplatin in advanced biliary tract cancer (ZSAB-TOP): a multicenter, single-arm, phase 2 study [PDF]

Guo‐Ming Shi, Xiaoyong Huang, Liang Ma, Hui Li, Jian‐Hong Zhong, Junye Wang, Qiang Gao, Xiaojun Guo, Shuang‐Jian Qiu, Hui‐Chuan Sun, Yongyong Shi, Xiaowu Huang, Xiaoying Wang, Yong Yi, Xiaodong Zhu, Cheng Huang, Zhen‐Bin Ding, Yi Chen, Yifeng He, Ying-Hao Shen, Qi‐Man Sun, Jian Zhou, Jia Fan   +22 more
openalex   +1 more source

Neoadjuvant Under‐Dilated TIPS: Expanding Surgeries for Extrahepatic Malignancies in Patients With Cirrhosis and CSPH

Liver International, Volume 46, Issue 1, January 2026.
ABSTRACT Background & Aims Portal hypertension is a major challenge in patients with cirrhosis requiring surgery. This study aimed to evaluate the efficacy of under‐dilated neoadjuvant transjugular intrahepatic portosystemic shunt (U.N‐TIPS) in enabling elective extrahepatic oncologic surgery in patients with cirrhosis and clinically significant portal
Dario Saltini, Davide Roccarina, Marco Senzolo, Cristian Caporali, Fabrizio Fanelli, Marcello Bianchini, Federico Casari, Angelica Ingravallo, Silvia Aspite, Tomas Guasconi, Antonio Piscopo, Andrea Salome Velasco Mayorga, Barbara Catellani, Gian Piero Guerrini, Stefano Di Sandro, Fabio Staderini, Umberto Cillo, Fabrizio Di Benedetto, Antonio Colecchia, Fabio Marra, Patrizia Burra, Francesco Vizzutti, Filippo Schepis   +22 more
wiley   +1 more source

FAM111B Suppression Enhances Sensitivity to Gemcitabine in Pancreatic Cancer Through Intracellular pH Regulation. [PDF]

Cancer Sci
Nishimura M, Sunagawa M, Kokuryo T, Yamaguchi J, Baba T, Mizuno T, Onoe S, Watanabe N, Kawakatsu S, Ebata T.   +9 more
europepmc   +1 more source

Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers

CA: A Cancer Journal for Clinicians, Volume 76, Issue 1, January/February 2026.
Abstract The therapeutic landscape for renal cell carcinoma (RCC) and urinary tract cancer (UTC) has transformed dramatically, creating complexity in treatment selection and sequencing. The 2025 Advanced Urologic Cancer Consensus Conference was convened to establish evidence‐based expert consensus recommendations for optimal management.
Rana R. McKay, Sumanta Pal, Wanling Xie, David Aggen, Laurence Albiges, Andrea Apolo, Michael B. Atkins, Rick Bangs, Kathryn E. Beckermann, Joaquim Bellmunt, Stephanie A. Berg, Mehmet A. Bilen, David Braun, Maria I. Carlo, Jason Efstathiou, Matthew Galsky, Petros Grivas, Shilpa Gupta, Naomi Haas, A. Ari Hakimi, Hans Hammers, Daniel Y. C. Heng, Michelle Hirsch, Gopakumar Iyer, Eric Jonasch, Vadim S. Koshkin, Oleksandr Kryvenko, Bryan Lewis, Roger Li, Surena Matin, Benjamin Maughan, David F. McDermott, Bradley McGregor, Joshua Meeks, Matthew Milowsky, Robert Motzer, Andrea Necchi, Dan Petrylak, Sima Porten, Thomas Powles, Brian Rini, Brian Shuch, Arlene Siefker‐Radtke, Guru Sonpavde, S. Srikala Sridhar, Cristina Suarez, Chad Tang, Abhishek Tripathi, Michiel S. Van Der Heijden, Martin Voss, Wenxin Xu, Tian Zhang, Jonathan Rosenberg, Toni K. Choueiri   +53 more
wiley   +1 more source

GNAQ inhibits tumorigenesis via the ARHGEF25-mediated RHOA pathway in NK/T-cell lymphoma. [PDF]

Cancer Biol Ther
Gao Y, Zhang Z, Song Y, Song W, Li H, Zhang L, Li Z, Zhang M.   +7 more
europepmc   +1 more source

Dynasore as a dual modulator of lipid rafts and cell death in pancreatic cancer. [PDF]

Neoplasia
Hamilton JS, Garg RR, Thomas RM.
europepmc   +1 more source

The effect of common medications on the efficacy of immune checkpoint inhibitors

Cancer, Volume 131, Issue 24, 15 December 2025.
Abstract Background Medications such as proton pump inhibitors (PPIs), antihistamines, and nonsteroidal anti‐inflammatory drugs have been linked to immune checkpoint inhibitor (ICI) efficacy in patients with non–small cell lung cancer (NSCLC), but these associations may reflect unmeasured confounding rather than true pharmacologic effects.
Daria Brinzevich, Virginia Falvello, Sadiq S. Rehmani, Garth W. Strohbehn, Nithya Ramnath, Michael P. Dykstra, Luke M. Higgins, David Elliott, Matthew J. Schipper, Michael D. Green, Alex K. Bryant   +10 more
wiley   +1 more source

Advanced intestinal-type ampullary cancer successfully treated using combination therapy with gemcitabine, cisplatin, and durvalumab: A case report. [PDF]

SAGE Open Med Case Rep
Hanatani JI, Kitagawa K, Asada S, Motokawa Y, Osaki Y, Iwata T, Kaji K, Mitoro A, Tsujimura M, Yoshiji H.   +9 more
europepmc   +1 more source